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Abstract
Background: There has been substantial growth in the numbers of patients with conjunctival squamous cell carcinoma
infected with HIV in East Africa. The natural history of the conjunctival squamous cell carcinoma appears to be unique in this
region of the world, but the etiologic mechanism unclear and therapeutic options limited. This research was carried out to
determine if conjunctival squamous cell carcinoma harbors human papillomavirus DNA and is associated with activation of
the EGFR signaling pathway. Positive findings would identify etiologic causes and provide clinical guidance to improve
treatment.
Methods/Findings: Expression of p-MAPK/MAPK, p-Akt/Akt and p-EGFR/EGFR in cell nuclei and cytoplasm of 38 FFPE
specimens were assessed by immunohistochemistry; HPV genotype was detected by qPCR assay; EGFR mutation was
assessed by DNA sequencing analysis; and EGFR mRNA expression was measured using relative qPCR. Statistical analyses
included two-sided Fisher exact test or chi-square test, Spearman correlation coefficient and ANOVA. HPV 18 was found in
61% of samples, with HPV 16 double-genotype in 6 patients (16%). Immunohistochemistry and qPCR data suggest that
activation and expression of the EGFR signaling pathway is related to disease progression of conjunctival cancer. The
associations between cytoplasmic p-MAPK, cytoplasmic p-Akt and tumor invasiveness were significant (p=0.05 or 0.028).
Nuclear p-EGFR appeared only in invasive tumors. A significant positive association between EGFR expression and disease
invasiveness was observed (p=0.01). A SNP in 10 patients and one missense mutation were found within EGFR tyrosine
kinase domain. Statistical analysis indicates that patients with measurable EGFR expression more likely harbor EGFR
mutations, compared to those with negative EGFR expression (35.3% vs. 0%).
Conclusions/Significance: We conclude that HPV types 16/18 infection is frequent in East African patients with AIDS-
associated squamous cell carcinoma of the conjunctiva. EGFR activation/alteration may contribute to and sustain the high
prevalence of this cancer. Our findings hint that adoption of HPV vaccination strategies may impact the incidence of
conjunctival carcinoma. Agents that target the EGFR pathway may have potential therapeutic benefit.
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Introduction
An association between human immunodeficiency virus (HIV)
infection and squamous cell carcinoma of the conjunctiva was first
reported in the mid-1990s. Since then there has been a substantial
increase in patients with conjunctival squamous cell carcinoma
infected with HIV in East Africa [1,2]. In 1995, Ateenyi-Agaba
observed that a high incidence of these tumors in Uganda appeared
to be related to HIV infection [3]. Waddell and colleagues suggested
that HIV infection is strongly associated with an increase in the
incidence of conjunctival carcinoma in Africa and that immuno-
suppression from HIV facilitates activity of other infective agents
that induce the carcinoma [4]. Recently, a pathophysiologic study
found that HPV types 16 and 18 play a critical role in the
oncogenesis of conjunctival cancers in subtropical Tanzania [5].
Thus, conjunctival squamous cell carcinoma is of growing concern
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10477in East Africa. The natural history of this disease appears to be
unique in this region of the world, though the etiologic mechanism is
unclear and therapeutic options remain limited.
Human papillomaviruses (HPV) are a group of host-specific
DNA viruses with 15 high-risk or oncogenic subtypes which have
been shown to act as carcinogens in the development of cervical,
anogenital and conjunctival squamous cell cancers. Persistent HPV
infections are the major cause of cervical cancer and contribute to
other cancers [6,7]. Studies indicate that viral oncoproteins
encoded by HPV can disturb cellular responses to signals
emanating from growth factor-linked signal transduction pathways,
such as those mediated by EGFR, an important cellular survival
factor [8]. Oncoprotein E5, encoded by HPV16, enhances the
activation of the epidermal growth factor receptor and its
downstream signal transduction pathways through the MAP kinase
activity [9–11]. The E6 oncoprotein, encoded by HPV16 and
HPV18, is known to bind the tumor suppressor gene product p53
and promotes p53 degradation [12]. The E7 oncoprotein, encoded
by HPV16 and HPV18, binds to the retinoblastoma tumor
suppressor gene product pRB and results in E7-induced inactiva-
tion of pRB [13]. The E5 protein cooperates with E7 to transform
cells and enhances the ability of E7 to induce proliferation, and
with E6 to immortalize cells [9]. Abundant preclinical and clinical
data suggest that blocking the function of EGFR can enhance the
efficacy of chemotherapy and radiotherapy and promote tumor
regression in epithelial and squamous carcinomas [14].
We hypothesized that a proportion of squamous cell carcinoma
of the conjunctiva, a unique AIDS-associated malignancy in
equatorial Africa, would harbor human papillomavirus (HPV)
DNA. Given it is an epithelial malignancy, the epidemiologic and
demographic similarities between Kaposi’s sarcoma and lympho-
ma seen in the background of HIV/AIDS in this region, we also
suspected there would be evidence of activation of the epidermal
growth factor receptor signaling cascade. Moreover, we proposed
that an exploratory tissue-based study would provide evidence for
the relation of HPV infection and EGFR signaling in this tumor
type and serve as a guide for clinical trials investigating targeted
agents or other therapeutic strategies.
Three major methodologies have been used in the past for
detection of specific types of HPV DNA in specimens from cancer
patients: antibodies against various HPV types for immunohisto-
chemistry (IHC); fluorescence in situ hybridization (FISH); and
polymerase chain reaction (PCR) in blood, biopsies and formalin-
fixed paraffin-embedded (FFPE) tissue samples [15–18]. These
methodologies provided preliminary information to open this area
of research. Unfortunately, there are conflicting reports on the
classification of tumor associated HPV subtypes and unclear
directions for clinical trials and therapeutic strategies due to the
limited sensitivity of available assays [19]. In this investigation we
applied quantitative PCR (qPCR) to classify HPV genotypes.
Materials and Methods
Ethics Statement
Archived FFPE samples from patients with squamous cell
carcinoma of the conjunctiva were obtained from the Uganda
Cancer Registry in Kampala and the Pathology Department at the
Kenyatta National Hospital in Nairobi, Kenya. Before the samples
were shipped for analysis, they had been stripped of all patient
identifiers. There is no way of linking molecular laboratory data with
any subject in this study. Accordingly, ethical approval was not
necessary as there were no risks to human subjects. Furthermore, no
clinical data was abstracted from the medical records and at time of
retrieval most of these patients were presumed dead.
Human Samples
We examined 38 FFPE specimens obtained from Ugandan and
Kenyan patients with documented HIV infection and biopsy-
proven conjunctival squamous intraepithelial neoplasia (spanning
the spectrum of dysplasia, in situ disease and invasive tumor as
shown in Table 1). These de-identified tumor samples were
retrieved from archives in the Departments of Pathology at the
Makerere University School of Medicine and Uganda Cancer
Institute; the Kampala Tumor Registry; and the Kenyatta
National Hospital and the University of Nairobi College, Health
Sciences in Kenya. Hematoxylin and eosin stained slides were
reviewed by pathologists (DD and JW) to confirm diagnosis. For
detection of HPV DNA genotypes, slides were stained using the
Arcturus histogene kit and areas of squamous intraepithelial
neoplasia were acquired using Laser Capture Microdissection
(LCM). Additional tumor tissue slides were prepared for
immunohistochemistry using standard techniques. For DNA and
RNA studies of EGFR mutations and quantitation of EGFR
mRNA, adjacent tumor tissues around the LCM residue were
collected from the tissue block.
DNA Extraction
Prior to LCM, samples were de-paraffinized with xylene and
sequentially washed with a graded series of ethanol solutions
(100%, 95% and 75%) stained and dehydrated using the protocol
and reagents from an Arcturus histogene kit. Approximately 500
to 1,000 tumor cells were captured via LCM by a pathologist using
the Arcturus Veritas system (MDS Analytical Technologies,
Concord, ON). Tumor DNA extraction was performed using
the Pico Pure DNA Extraction kit (ARCTURUS Bioscience, Inc.,
Mountain View, CA). The cells were extracted by insertion of
laser-captured caps into an Eppendorf tube containing digestion
buffer [50 ml buffer containing 0.04% Proteinase K, 10 mM Tris-
HCL (pH 8.0), 1 mM EDTA, and 1% Tween-20]. The
equilibrated cells were incubated in the above reaction for 24 hr
at 65uC. After 5-min centrifugation, the DNA-containing solution
was heated at 95uC for 8 min to inactivate proteinase K.
RNA Isolation and cDNA Generation
The total RNA was extracted using the RecoverAll Total Nucleic
Acid Isolation kit (Ambion Inc., Austin, TX) according to the
manufacturer’s protocol. In brief, a 1–1.5 mm
3 tumor section of the
sample was collected in a microtube, deparaffinized with 100%
xylene at 50uC for 3 min, and washed with 100% ethanol. Then,
4 ml protease K and 200 ml digestion buffer were added to each
s a m p l ea n di n c u b a t e da t6 5 uC for 3 hr. Isolation additive/ethanol
mixture was applied and then the mixture was passed through a
filter cartridge. DNase mix was added to the buffer-washed cartridge
for 30 min. The elute RNA was collected using 30 mln u c l e a s e - f r e e
water and the RNA was stored at 280uC. cDNAs were generated
from 5 mg of total RNA per sample via SuperScript II reverse
transcriptase (Invitrogen Corp., Carlsbad, CA).
Table 1. Pathological classification of Patient Specimens
Infected by HPV 16/18 Genotypes.
Patient Specimens Dysplasia In situ Disease Invasive Tumor
(Total 38) 5 22 11
HPV 16 Infection 0 3 3
HPV 18 Infection 5 12 6
doi:10.1371/journal.pone.0010477.t001
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HPV 16 and HPV 18 were selected because they are the
common high-risk types in several cancers [9–12]. HPV 59 and
HPV 52 were the most and the next most frequently detected high-
risk types in the external genitalia [20]. These four genotypes were
determined using a TaqMan-based quantitative PCR analysis.
Type-specific primers and probes for HPV types 16, 18, 52 and 59
were selected to target genome segments of the E6/E7 region as
previously reported [21]. These primers and FAM-labeled probes
were synthesized by Applied Biosystems (Forster City, CA). All
reactions were undertaken in a final volume of 20 ml containing
TaqManH Gene Expression Master Mix, tumor genomic DNA
and HPV type-specific primers and probe. Amplification was
performed in separate reactions for each of the 4 HPV types in a
96-well plate. The PCR was run 2 min at 50uC, 10 min at 95uC,
and 40 cycles of 15 seconds at 95uC and 1 min at 60uC on an ABI
7500 Fast Real-Time PCR System. A high PCR efficiency for each
component PCR was verified by analyzing serial dilution of
synthesized standard DNA containing targeted segments of each
HPV type, sized 74 -110 base pairs (synthesized by Sigma Life
Sciences, St. Louis, MO). Additional two-triplicates containing all
PCR components except template DNA were denoted no template
control (NTC) to ensure that the reagents were free of
contamination. Finally, Ct (threshold cycle), DCt, DDCt, AQ or
RQ and gene expression plots were generated by the 7500 Fast
System SDS Software (Version 1.4). In this study, a Ct value was
,35 considered as positive expression, and vice versa.
Absolute Quantitation (AQ) for HPV genotyping
For AQ detection in addition to the above procedures, we used
Hela-cell genomic DNA for HPV type 18 and synthesized DNA for
types 16, 52 and 59 for standard curves. The curve was drawn by 5
serial dilutions of the above known-input-target copies (3 replicates for
each concentration) vs. the corresponding Ct values using the least-
squares fit method. Dissociation protocol was applied to confirm the
targeted PCR products. Given the standard curve, the system
software interpolates the absolute quantity of target in each sample.
Relative Quantitation (RQ) for HPV genotyping
For RQ detections, RNase-P Master Mix was used as
endogenous control in duplicate in the 20 ml reaction. The Ct
and comparative DDCt were automatically calculated for the
expression of the gene and normalized to mean Ct value of
RNase-P. The RQ value was calculated using DDCt method. Fold
change in gene expression was calculated as 2
2 DDCt.
EGFR mRNA Expression by Real-Time RQ PCR
cDNA generated from 5 mg of total RNA for each sample was
used in this assay. Primers and FAM-labeled probes of the tyrosine
kinase domain (exons 20–21) of the EGFR gene were purchased
from Applied Biosystems. Human 18S rRNA was applied in
duplicate as endogenous control. The remaining procedures were
as described for RQ PCR for HPV detection.
EGFR Mutation Analyses
Tumor DNA was amplified by polymerase chain reaction with
primers for each exon (18, 19, 20 and 21) of the EGFR tyrosine
kinase domain and AmpliTaq DNA polymerase, FS. In brief, five
nanograms of DNA were used for the first PCR reaction and
2.5 ml of the first PCR products were applied for nested PCR [22].
PCR amplicons were separated on agarose gel and purified using a
QIAQuick Gel Extraction Kit (Qiagen, Germantown, MD). The
purified fragments were sequenced to identify EGFR mutations on
a CEQ 8000 Genetic Analysis System with DTCS Quick Start kit
(Beckman Coulter, Fullerton, CA). All sequence variants were
confirmed in duplicate independent PCR amplifications and
sequencing reactions to insure that detected mutations were not
the result of PCR artifact.
MAP Kinase, Akt and EGFR Immunohistochemistry
Immunohistochemistry for MAP Kinase, Akt and EGFR were
performed on FFPE tissue. Sections (5 mm thick) on positively
Figure 1. Prevalence of high-risk HPV genotypes in conjunc-
tival squamous cell carcinoma by real-time RQ PCR assay.
Tumor DNA extraction was performed using Pico Pure DNA Extraction
kit. The viral DNA of 4 HPV genotypes were determined using a
TaqMan-based real-time quantitative PCR analysis. Type-specific prim-
ers and probes for HPV types 16, 18, 52 and 59 were selected to target
genome segments of the E6/E7 region and synthesized by Applied
Biosystems. RNase-P as endogenous control for each sample (in
duplicate) was applied in this assay. Amplification results from the
endogenous control were used to normalize the amplification results
from the target HPV types. Finally, Ct, DCt, DDCt, RQ and gene
expression plots were generated by the ABI 7500 Fast System SDS
Software (Version 1.4).
doi:10.1371/journal.pone.0010477.g001
Table 2. Association between cytoplasmic phospho-MAPK and pathological classification.
Cytoplasmic p-MAPK Dysplasia (row %) In situ (row %) Invasive cancer (row %) p-value
IHC Score 1 and 2 (Negative) 4 (20) 8 (40) 8 (40) 0.05
IHC Score 3 and 4 (Positive) 0 (0) 3 (20) 12 (80)
doi:10.1371/journal.pone.0010477.t002
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antigen retrieval in 10 mmol/l citrate buffer (pH 6.0) in a steamer
at 98uC for 45 min. Staining was performed using polyclonal
rabbit anti-P44/42 and anti-Phospho-P44/42 MAP Kinases or
anti-Akt (Ser473) and anti-p-Akt (Ser473) antibodies (1:100
dilution) or monoclonal rabbit anti-EGFR (1:25 dilution) and
anti-phospho-EGFR (Tyr1173; 1:50 dilution) from Cell Signaling
Technology, Inc. (Danvers, MA), DAKO EnVision systems
(DAKO Corporation, Carpinteria, CA), and chromogen 3,39-
diaminobenzidine tetrahydrochloride. The staining intensity of the
conjunctival squamous cell carcinoma was compared with that of
adjacent non-neoplastic tissue by semiquantitative visual evalua-
tions by two observers (DD and JW). In immunohistochemistry
data from these patients, we utilized the standard convention
staining of 3 and 4 scores as positive, and of 1 and 2 as negative for
statistical analysis.
Statistical Analysis
The association between two factors was examined by Fisher
e x a c tt e s to rc h i - s q u a r et e s t .T h ea s s o c i a t i o nb e t w e e nt w o
ordinal variables was estimated by Spearman correlation
coefficient. The difference of the ratio of phospho-MAPK
(Akt, EGFR) to total MAPK (Akt, EGFR) among 3 types of
tissues (dysplasia, in situ disease and invasive tumor) was
examined by ANOVA. All statistical analyses were two-sided
and done using SAS (SAS Institute, Cary, NC), and p-value
#0.05 was considered statistically significant.
Results
Prevalence of HPV infection is high in conjunctival
squamous intraepithelial neoplasia of HIV-infected
patients in East Africa
Viral DNA of high-risk HPV genotypes 16 and 18 was detected
in surveyed specimens by absolute- and relative-quantitation real-
time PCR assays. HPV 18, the most common oncogenic strain,
was found in 23 of 38 (61%) conjunctival cancer patients. Three in
situ diseases and 3 invasive tumors of the 23 HPV 18 positive
patients also showed coincident HPV 16 infection (i.e., double
genotypes of HPV 16 and 18). High-risk HPV types 52 and 59
were not characterized in these samples (Table 1 & Fig. 1). This
technique appears to be a sensitive, reproducible and reliable
method to determine HPV genotypes in FFPE samples of
conjunctival squamous cell carcinoma.
Activation of EGFR signaling pathway is related to
disease progression of conjunctival squamous cell
carcinoma
Nuclear and cytoplasmic expression of phosphorylated
and total EGFR and two downstream effectors of the EGFR
signal-transduction pathway, MAPK and Akt, were assessed in
tissue specimens by immunohistochemistry. We observed p-
MAPK/MAPK and p-Akt/Akt in both the cytoplasm and
nuclei of cells, in contrast to p-EGFR/EGFR, which was
observed only in the nuclei. Statistical analyses of immunohis-
tochemistry data demonstrated significant relationships be-
tween phosphorylated-MAPK or phosphorylated-Akt and
disease invasiveness (Tables 2 and 3). The associations between
cytoplasmic p-MAPK, cytoplasmic p-Akt and tumor invasive-
ness were significant (p=0.05 or 0.028). In addition, there was
some evidence that nuclear p-Akt was predictive of tumor
invasiveness (p=0.089) (Table 4). In tumors expressing nuclear
p-Akt, 72.2% were invasive compared to 44.4% in tumors
without nuclear p-Akt (Table 4). Though our results for
EGFR protein expression did not show a direct correlation,
nuclear p-EGFR staining was only present in invasive cancers
(Table 5).
EGFR mRNA expression is significantly correlated with
tumor invasiveness in conjunctival squamous cell
carcinoma patients
We investigated EGFR mRNA expression in these samples by
real-time RQ PCR using primers and probes selected within the
tyrosine kinase domain (exons 20–21) of the EGFR gene. In this
series, EGFR mRNA expression was measured in tissues from
22 patients. Seventeen of 22 patients (77%) showed EGFR
mRNA expression (Table 6). We also observed that EGFR
mRNA expression correlated with nuclear p-EGFR protein
expression (data not shown). As expected, a significant positive
association between EGFR expression and disease invasiveness
was observed (p=0.01). Of all EGFR positive tumors 70.6%
were invasive, while 0% of the EGFR negative tumors were
invasive (Table 6).
Table 3. Association between cytoplasmic phospho-Akt and pathological classification.
Cytoplasmic p-Akt Dysplasia (row %) In situ (row %) Invasive cancer (row %) p-value
IHC Score 1 2 (9.5) 11 (52.4) 8 (38.1)
IHC Score 2 1 (12.5) 0 (0) 7 (87.5) 0.028
IHC Score 3 0 (0) 0 (0) 1 (100)
IHC Score 4 1 (25) 0 (0) 3 (75)
doi:10.1371/journal.pone.0010477.t003
Table 4. Association between nuclear phospho-Akt and pathological classification.
Nuclear p-Akt Dysplasia (row %) In situ (row %) Invasive cancer (row %) p-value
IHC Score 1 and 2 (Negative) 3 (16.7) 7 (38.9) 8 (44.4) 0.089
IHC Score 3 and 4 (Positive) 1 (5.6) 4 (22.2) 13 (72.2)
doi:10.1371/journal.pone.0010477.t004
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EGFR alteration
EGFR mutational status was assessed in the patient tumor DNA
of the conjunctival squamous cell carcinoma through DNA
sequencing analysis. Among the 38 assessed samples, one missense
mutation was found; a C to T transversion within exon 20 of the
EGFR gene, resulting in a substitution of the 767 alanine for a
valine. In addition, a G to A transition within EGFR exon 20 was
detected in 10 of the 38 examined samples, resulting in a SNP
(Silent Gln 787 Gln; data not shown). No other sequence
alterations were detected in exons 18, 19 and 21 of the EGFR
tyrosine kinase domain in these samples. Our analysis indicated no
statistically significant association between EGFR expression and
EGFR exon-20 mutation (Table 7). However, samples with
positive EGFR expression were more likely to have EGFR
mutation, compared to those with negative EGFR expression
(35.3% vs. 0%) (Table 7).
Discussion
The EGFR gene is located on chromosome 7p12 and codes for
a 170 kD receptor, present on the membrane of cells as inactive
monomers. Upon ligand binding to the extracellular domain, the
receptor undergoes conformational changes, dimerizes and
becomes autophosphorylated in key tyrosine residues in the
intracellular tyrosine kinase domain. This leads to the activation
of downstream pathways, including MAPK and PI3K/Akt
pathways, which control cell survival, inhibition of apoptosis,
and proliferation [23]. EGFR-mutation is one of the most frequent
genetic changes found in human cancers [24]. Much attention has
been given to the oncogenic effect of the EGFR gene and EGFR-
targeted therapies.
This study used phospho-specific antibodies directed at
activated EGFR and downstream effectors to characterize
expression, state of constitutive activation and subcellular
translocation. The results revealed the constitutive activation and
overexpression of the MAPK/Akt pathways. Specifically, we
observed 1) increased expression of phosphorylated (Tyr1173),
nuclear EGFR; the upstream tyrosine kinase that transduces
signals through both the PI3K/Akt and MAPK pathways, thereby
contributing to constitutive activation of these signaling pathways
in conjunctival squamous cell carcinomas and 2) correlative
downstream overexpression of nuclear -phospho-P44/42 MAPK
and phospho-Akt (Ser473). These observations are consistent with
the findings of Shepler’s group that there is frequent EGFR
amplification and MAPK and Akt phosphorylation in conjunctival
squamous cell carcinomas; of Chen and colleagues and Kohren-
hagen’s group that increased expression of p-MAPK and p-Akt
appeared during tumor progression of cervical neoplasms [25–27].
Development of adenocarcinoma of the uterine cervix and
squamous cell carcinoma is strongly linked to infection by high-risk
HPV types [28,29]. There is molecular evidence that viral
oncoproteins (E5, E6 and E7) found in high-risk HPV genotypes
inactivate the tumor suppressor proteins p53 and pRb, promote
genomic rearrangement, and confer replicative and immortalizing
activities in cervical neoplasms, conjunctival squamous cell
carcinoma and other cancers [12,13,30,31].
Our studies indicate a possible mechanism by which the
oncoproteins E5, E6 and E7, encoded by high-risk HPV
genotypes, activate EGFR signal transduction and lead to
increased signaling through the MAPK/Akt pathways, resulting
in unchecked cellular proliferation. In other words, activation of
the EGFR pathway in conjunctival squamous cell carcinoma
appears to play a role in genetic alteration to maintain a malignant
phenotype, as a consequence of the genomic instability associated
with HPV infection. These findings are consistent with our
understanding of the effects of HPV, the principle etiologic agent
associated with EGFR activity, in providing etiopathogenic insight
into HIV-infected conjunctival carcinoma development.
In conclusion, our study demonstrated that TaqMan real-time
qPCR assay is a sensitive and reliable method for detection of
specific HPV genotypes in formalin-fixed, paraffin-embedded
tumor samples. Our findings also suggest that constitutively
activated and overexpressed MAPK/Akt, acting in concert with
EGFR overexpression/alteration, and in collaboration with viral
oncoproteins, play a key role in conjunctival carcinoma oncogen-
esis. Further investigation of the mechanisms of HPV-oncoprotein
effects on EGFR activation/alteration is warranted. Our findings
hint that adoption of HPV vaccination strategies may impact the
incidence of conjunctival squamous cell carcinoma and use of
Table 5. Association between nuclear phospho-EGFR and pathological classification.
Nuclear p-EGFR Dysplasia (row %) In situ (row %) Invasive cancer (row %) p-value
IHC Score 1 0 (0) 0 (0) 9 (100)
IHC Score 2 0 (0) 0 (0) 6 (100) NA
IHC Score 3 0 (0) 0 (0) 6 (100)
doi:10.1371/journal.pone.0010477.t005
Table 6. Association between EGFR mRNA expression and
pathological classification.
EGFR mRNA
expression
(Total 22)
Dysplasia
(row %)
In situ
(row %)
Invasive cancer
(row %) p-value
Not Expressed (2) 1 (20) 4 (80) 0 (0) 0.01
Expressed (+) 1 (5.9) 4 (23.5) 12 (70.6)
doi:10.1371/journal.pone.0010477.t006
Table 7. Patients with EGFR expression are more likely to
have EGFR mutation.
EGFR Exon-20 mutation
EGFR expression
Wild Type
(row %)
Mutation
(row %) p-value
Not Expressed (2) 5 (100) 0 (0) 0.266
Expressed (+) 11 (64.7) 6 (35.3)
doi:10.1371/journal.pone.0010477.t007
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pathway may have potential therapeutic benefit.
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